- Previous Close
42.67 - Open
42.67 - Bid 40.88 x 100
- Ask 41.19 x 100
- Day's Range
40.91 - 43.14 - 52 Week Range
15.58 - 48.89 - Volume
597,249 - Avg. Volume
599,918 - Market Cap (intraday)
2.446B - Beta (5Y Monthly) 2.16
- PE Ratio (TTM)
14.98 - EPS (TTM)
2.74 - Earnings Date Nov 7, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
54.38
Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
www.protagonist-inc.comRecent News: PTGX
View More
Performance Overview: PTGX
Trailing total returns as of 11/14/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: PTGX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: PTGX
View MoreValuation Measures
Market Cap
2.54B
Enterprise Value
2.09B
Trailing P/E
15.57
Forward P/E
714.29
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
8.38
Price/Book (mrq)
4.78
Enterprise Value/Revenue
6.44
Enterprise Value/EBITDA
13.69
Financial Highlights
Profitability and Income Statement
Profit Margin
52.76%
Return on Assets (ttm)
19.96%
Return on Equity (ttm)
40.97%
Revenue (ttm)
323.8M
Net Income Avi to Common (ttm)
170.85M
Diluted EPS (ttm)
2.74
Balance Sheet and Cash Flow
Total Cash (mrq)
468.72M
Total Debt/Equity (mrq)
2.05%
Levered Free Cash Flow (ttm)
144.94M
Research Analysis: PTGX
View MoreCompany Insights: PTGX
PTGX does not have Company Insights
Research Reports: PTGX
View MoreLowering target price to $45.00
PROTAGONIST THERAPEUTICS INC has an Investment Rating of HOLD; a target price of $45.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Low.
RatingPrice TargetLowering target price to $48.00
PROTAGONIST THERAPEUTICS INC has an Investment Rating of HOLD; a target price of $48.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of High; a Growth Subrating of Medium; and a Value Subrating of Low.
RatingPrice TargetRaising target price to $51.00
PROTAGONIST THERAPEUTICS INC has an Investment Rating of HOLD; a target price of $51.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of High; and a Value Subrating of Low.
RatingPrice TargetLowering target price to $49.00
PROTAGONIST THERAPEUTICS INC has an Investment Rating of HOLD; a target price of $49.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of High; and a Value Subrating of Low.
RatingPrice Target